Skip to content

Late-term Abortions Between 14 and 16 Weeks of Gestation: Comparison of Hemorrhagic Risks in Surgical vs. Medical Abortions

Late-term Abortions Between 14 and 16 Weeks of Gestation: Comparison of Hemorrhagic Risks in Surgical vs. Medical Abortions

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07335939
Acronym
IVG-Tardives
Enrollment
50
Registered
2026-01-13
Start date
2025-05-19
Completion date
2026-06-19
Last updated
2026-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abortion Late

Keywords

Abortion Late, Ongoing single pregnancy, Ongoing multiple pregnancy

Brief summary

Since the extension of the legal abortion limit to 16 weeks by the law of March 2, 2022, we must adapt our care to reduce the risks associated with this procedure. According to the French National Authority for Health (HAS), all abortions after 9 weeks of gestation should be performed surgically, but the French National College of Gynecologists and Obstetricians (CNGOF) indicates that each patient should have the choice of method regardless of the gestational age at the time of the abortion.

Interventions

None listed

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Adult woman * Single or multiple pregnancy * Undergoing an abortion between 14 and 16 weeks of gestation at the Strasbourg University Hospital between March 2, 2022, and March 2, 2026

Exclusion criteria

* Missed Pregnancy * Term \< 14 Weeks of Gestation or \> 16 Weeks of Gestation

Design outcomes

Primary

MeasureTime frameDescription
Bleeding (in cc)During surgeryBleeding \> 500 cc means a very large blood loss

Countries

France

Contacts

Primary ContactVictor Gabrielle, MD
Victor.gabriele@chru-strasbourg.fr33 3 69 55 34 04

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026